Trial Outcomes & Findings for LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma (NCT NCT00062868)
NCT ID: NCT00062868
Last Updated: 2020-06-09
Results Overview
Dose limiting toxicity (DLT) rate is the proportion of participants with DLT. DLT will be defined as any toxicity that is irreversible, life threatening or Grade 3-4 considered to be primarily related to the LMP-specific cytotoxic T-lymphocytes (CTL) injection or development of Grade III-IV Graft versus host disease (GVHD). Toxicity will be evaluated according to the CTCAE Version 2.0. GVHD will be graded by the method of Przepiorka et al (protocol Appendix I).
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
74 participants
Primary outcome timeframe
6 weeks post second CLT infusion
Results posted on
2020-06-09
Participant Flow
Participant milestones
| Measure |
LMP2A CTLs (ALASCER) - Group A DL1
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group A DL2
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group A DL3
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL1
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL2
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL3
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL1
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL2
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL3
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL1
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL2
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL3
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL1
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL2
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL3
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL1
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL2
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL3
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A Expansion
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B Expansion
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C Expansion
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dose Level 1
STARTED
|
3
|
0
|
0
|
3
|
0
|
0
|
4
|
0
|
0
|
3
|
0
|
0
|
3
|
0
|
0
|
3
|
0
|
0
|
16
|
2
|
3
|
|
Dose Level 1
COMPLETED
|
1
|
0
|
0
|
1
|
0
|
0
|
1
|
0
|
0
|
3
|
0
|
0
|
2
|
0
|
0
|
3
|
0
|
0
|
7
|
2
|
1
|
|
Dose Level 1
NOT COMPLETED
|
2
|
0
|
0
|
2
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
9
|
0
|
2
|
|
Dose Level 2
STARTED
|
0
|
6
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
4
|
0
|
0
|
3
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
|
Dose Level 2
COMPLETED
|
0
|
3
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Dose Level 2
NOT COMPLETED
|
0
|
3
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
|
Dose Level 3
STARTED
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
0
|
3
|
0
|
0
|
4
|
0
|
0
|
0
|
|
Dose Level 3
COMPLETED
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
0
|
0
|
2
|
0
|
0
|
3
|
0
|
0
|
0
|
|
Dose Level 3
NOT COMPLETED
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
0
|
0
|
1
|
0
|
0
|
0
|
Reasons for withdrawal
| Measure |
LMP2A CTLs (ALASCER) - Group A DL1
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group A DL2
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group A DL3
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL1
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL2
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL3
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL1
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL2
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL3
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL1
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL2
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL3
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL1
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL2
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL3
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL1
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL2
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL3
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A Expansion
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B Expansion
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C Expansion
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dose Level 1
Death
|
2
|
0
|
0
|
2
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
0
|
1
|
|
Dose Level 1
Lost to Follow-up
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
1
|
|
Dose Level 2
Death
|
0
|
3
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
|
Dose Level 2
Lost to Follow-up
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
Dose Level 3
Death
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
Dose Level 3
Lost to Follow-up
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Dose Level 3
Withdrew
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Baseline Characteristics
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Baseline characteristics by cohort
| Measure |
LMP2A CTLs (ALASCER) - Group A DL1
n=3 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group A DL2
n=6 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group A DL3
n=3 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL1
n=3 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL2
n=3 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL3
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL1
n=4 Participants
Group C: Participants receiving CTLs following allogeneic stem cell transplant. Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL2
Group C: Participants receiving CTLs following allogeneic stem cell transplant. Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL3
Group C: Participants receiving CTLs following allogeneic stem cell transplant. Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL1
n=3 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL2
n=4 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL3
n=5 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL1
n=3 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL2
n=3 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL3
n=3 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL1
n=3 Participants
Group C: Participants receiving CTLs following allogeneic stem cell transplant. Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL2
n=3 Participants
Group C: Participants receiving CTLs following allogeneic stem cell transplant. Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2)
|
LMP1/2 CTLs (ALCI) - Group C DL3
n=4 Participants
Group C: Participants receiving CTLs following allogeneic stem cell transplant. Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI - Expansion Group A)
n=16 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI - Expansion Group B)
n=2 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI - Expansion Group C)
n=3 Participants
Group C: Participants receiving CTLs following allogeneic stem cell transplant. Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2)
|
Total
n=74 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
39 years
n=5 Participants
|
53 years
n=7 Participants
|
13 years
n=5 Participants
|
57 years
n=4 Participants
|
25 years
n=21 Participants
|
—
|
54 years
n=8 Participants
|
—
|
—
|
46 years
n=42 Participants
|
54 years
n=42 Participants
|
55 years
n=42 Participants
|
23 years
n=36 Participants
|
18 years
n=36 Participants
|
43 years
n=24 Participants
|
13 years
n=135 Participants
|
30 years
n=136 Participants
|
17.5 years
n=44 Participants
|
45 years
n=667 Participants
|
39 years
n=12 Participants
|
16 years
n=12 Participants
|
33.5 years
n=12 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
—
|
1 Participants
n=8 Participants
|
—
|
—
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=24 Participants
|
1 Participants
n=135 Participants
|
2 Participants
n=136 Participants
|
2 Participants
n=44 Participants
|
7 Participants
n=667 Participants
|
0 Participants
n=12 Participants
|
2 Participants
n=12 Participants
|
27 Participants
n=12 Participants
|
|
Sex: Female, Male
Male
|
1 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
—
|
3 Participants
n=8 Participants
|
—
|
—
|
2 Participants
n=42 Participants
|
4 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
3 Participants
n=36 Participants
|
3 Participants
n=36 Participants
|
2 Participants
n=24 Participants
|
2 Participants
n=135 Participants
|
1 Participants
n=136 Participants
|
2 Participants
n=44 Participants
|
9 Participants
n=667 Participants
|
2 Participants
n=12 Participants
|
1 Participants
n=12 Participants
|
47 Participants
n=12 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
—
|
0 Participants
n=8 Participants
|
—
|
—
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=36 Participants
|
1 Participants
n=24 Participants
|
2 Participants
n=135 Participants
|
2 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
4 Participants
n=667 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=12 Participants
|
14 Participants
n=12 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
3 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
—
|
4 Participants
n=8 Participants
|
—
|
—
|
3 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
4 Participants
n=42 Participants
|
3 Participants
n=36 Participants
|
2 Participants
n=36 Participants
|
2 Participants
n=24 Participants
|
1 Participants
n=135 Participants
|
1 Participants
n=136 Participants
|
4 Participants
n=44 Participants
|
12 Participants
n=667 Participants
|
1 Participants
n=12 Participants
|
3 Participants
n=12 Participants
|
59 Participants
n=12 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
—
|
0 Participants
n=8 Participants
|
—
|
—
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
1 Participants
n=12 Participants
|
0 Participants
n=12 Participants
|
1 Participants
n=12 Participants
|
|
Race/Ethnicity, Customized
American Indian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
—
|
0 Participants
n=8 Participants
|
—
|
—
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
1 Participants
n=667 Participants
|
0 Participants
n=12 Participants
|
1 Participants
n=12 Participants
|
2 Participants
n=12 Participants
|
|
Race/Ethnicity, Customized
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
—
|
0 Participants
n=8 Participants
|
—
|
—
|
2 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
1 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=12 Participants
|
5 Participants
n=12 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
0 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
—
|
0 Participants
n=8 Participants
|
—
|
—
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
1 Participants
n=667 Participants
|
1 Participants
n=12 Participants
|
0 Participants
n=12 Participants
|
6 Participants
n=12 Participants
|
|
Race/Ethnicity, Customized
White
|
3 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
—
|
4 Participants
n=8 Participants
|
—
|
—
|
1 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
4 Participants
n=42 Participants
|
3 Participants
n=36 Participants
|
3 Participants
n=36 Participants
|
1 Participants
n=24 Participants
|
2 Participants
n=135 Participants
|
2 Participants
n=136 Participants
|
4 Participants
n=44 Participants
|
12 Participants
n=667 Participants
|
1 Participants
n=12 Participants
|
2 Participants
n=12 Participants
|
57 Participants
n=12 Participants
|
|
Race/Ethnicity, Customized
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
—
|
0 Participants
n=8 Participants
|
—
|
—
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
1 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
2 Participants
n=667 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=12 Participants
|
4 Participants
n=12 Participants
|
PRIMARY outcome
Timeframe: 6 weeks post second CLT infusionPopulation: Data is reported for all DLT evaluable participants who received CTL infusions and either completed the DLT assessment period or dropped off the study early due to DLT. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. DLT assessment data from the first enrollment is reported for this participant.
Dose limiting toxicity (DLT) rate is the proportion of participants with DLT. DLT will be defined as any toxicity that is irreversible, life threatening or Grade 3-4 considered to be primarily related to the LMP-specific cytotoxic T-lymphocytes (CTL) injection or development of Grade III-IV Graft versus host disease (GVHD). Toxicity will be evaluated according to the CTCAE Version 2.0. GVHD will be graded by the method of Przepiorka et al (protocol Appendix I).
Outcome measures
| Measure |
LMP2A CTLs (ALASCER) - Group A DL1
n=3 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group A DL2
n=6 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group A DL3
n=3 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL1
n=3 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL2
n=3 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL3
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL1
n=3 Participants
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL2
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL3
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL1
n=3 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL2
n=3 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL3
n=4 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL1
n=3 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL2
n=3 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL3
n=3 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL1
n=3 Participants
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL2
n=3 Participants
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL3
n=4 Participants
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A Expansion
n=15 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B Expansion
n=2 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C Expansion
n=2 Participants
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I)
|
0 proportion of participants
Interval 0.0 to 0.708
|
0 proportion of participants
Interval 0.0 to 0.459
|
0 proportion of participants
Interval 0.0 to 0.708
|
0 proportion of participants
Interval 0.0 to 0.708
|
0 proportion of participants
Interval 0.0 to 0.708
|
—
|
0 proportion of participants
Interval 0.0 to 0.708
|
—
|
—
|
0 proportion of participants
Interval 0.0 to 0.708
|
0 proportion of participants
Interval 0.0 to 0.708
|
0 proportion of participants
Interval 0.0 to 0.602
|
0 proportion of participants
Interval 0.0 to 0.708
|
0 proportion of participants
Interval 0.0 to 0.708
|
0 proportion of participants
Interval 0.0 to 0.708
|
0 proportion of participants
Interval 0.0 to 0.708
|
0 proportion of participants
Interval 0.0 to 0.708
|
0 proportion of participants
Interval 0.0 to 0.602
|
0 proportion of participants
Interval 0.0 to 0.218
|
0 proportion of participants
Interval 0.0 to 0.842
|
0 proportion of participants
Interval 0.0 to 0.842
|
SECONDARY outcome
Timeframe: Up to 4 months after the last infusionPopulation: Data is reported for all participants who has received at least one infusion and has available response assessment data. One participant in LMP1/2 CTLs (ALCI) - Group A Expansion is excluded because of no available response data and one was enrolled to this arm/group twice that response assessment data from the first enrollment is reported.
Response rate is defined as the proportion of participants with best overall response of complete response (CR) or partial response (PR) . All patients who receive the first infusion will be evaluable for response. In patients with detectable tumors and/or lymphadenopathy - response and progression will be evaluated using PET based imaging studies (whenever possible) based on the Harmonization Project (protocol 8.5.1). All available non-PET imaging studies will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.
Outcome measures
| Measure |
LMP2A CTLs (ALASCER) - Group A DL1
n=3 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group A DL2
n=6 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group A DL3
n=3 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL1
n=3 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL2
n=3 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL3
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL1
n=4 Participants
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL2
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL3
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL1
n=3 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL2
n=4 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL3
n=5 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL1
n=3 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL2
n=3 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL3
n=3 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL1
n=3 Participants
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL2
n=3 Participants
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL3
n=4 Participants
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A Expansion
n=15 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B Expansion
n=2 Participants
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C Expansion
n=3 Participants
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Response Rate According to the Harmonization Project (Protocol 8.5.1) or RECIST Criteria.
|
0.667 proportion of participants
Interval 0.094 to 0.992
|
0.833 proportion of participants
Interval 0.359 to 0.996
|
0.667 proportion of participants
Interval 0.094 to 0.992
|
0.333 proportion of participants
Interval 0.008 to 0.906
|
0.667 proportion of participants
Interval 0.094 to 0.992
|
—
|
0.75 proportion of participants
Interval 0.194 to 0.994
|
—
|
—
|
1 proportion of participants
Interval 0.292 to 1.0
|
0.75 proportion of participants
Interval 0.194 to 0.994
|
0.6 proportion of participants
Interval 0.147 to 0.947
|
1 proportion of participants
Interval 0.292 to 1.0
|
1 proportion of participants
Interval 0.292 to 1.0
|
1 proportion of participants
Interval 0.292 to 1.0
|
1 proportion of participants
Interval 0.292 to 1.0
|
0.667 proportion of participants
Interval 0.094 to 0.992
|
1 proportion of participants
Interval 0.398 to 1.0
|
0.733 proportion of participants
Interval 0.449 to 0.922
|
0.5 proportion of participants
Interval 0.013 to 0.987
|
0.333 proportion of participants
Interval 0.008 to 0.906
|
SECONDARY outcome
Timeframe: 6 weeks after the final injectionPopulation: Data is reported for participants who have received an extended dosage regimen.
Grade III-IV toxicity rate is defined as the proportion of participants who receive an extended dose regimen and developed Grade III-IV toxicity attributable to the CTL infusions at any time during the extended dosing regimen. Toxicity will be evaluated according to the CTCAE Version 2.0. GVHD will be graded by the method of Przepiorka et al (protocol Appendix I).
Outcome measures
| Measure |
LMP2A CTLs (ALASCER) - Group A DL1
n=2 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group A DL2
n=1 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group A DL3
n=1 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL1
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL2
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL3
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL1
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL2
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL3
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL1
n=1 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL2
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL3
n=1 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL1
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL2
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL3
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL1
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL2
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL3
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A Expansion
n=1 Participants
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B Expansion
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C Expansion
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Grade III-IV Toxicity Rate in Participants Receiving an Extended Dosage Regimen According to the NCI Common Toxicity Criteria (CTCAE) Version 2.0 and the Method of Przepiorka et. al. (Protocol Appendix I).
|
0 proportion of participants
Interval 0.0 to 0.842
|
0 proportion of participants
Interval 0.0 to 0.975
|
0 proportion of participants
Interval 0.0 to 0.975
|
—
|
—
|
—
|
—
|
—
|
—
|
0 proportion of participants
Interval 0.0 to 0.975
|
—
|
0 proportion of participants
Interval 0.0 to 0.975
|
—
|
—
|
—
|
—
|
—
|
—
|
0 proportion of participants
Interval 0.0 to 0.975
|
—
|
—
|
Adverse Events
LMP2A CTLs (ALASCER) - Group A DL1
Serious events: 2 serious events
Other events: 3 other events
Deaths: 2 deaths
LMP2A CTLs (ALASCER) - Group A DL2
Serious events: 1 serious events
Other events: 6 other events
Deaths: 3 deaths
LMP2A CTLs (ALASCER) - Group A DL3
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
LMP2A CTLs (ALASCER) - Group B DL1
Serious events: 1 serious events
Other events: 3 other events
Deaths: 2 deaths
LMP2A CTLs (ALASCER) - Group B DL2
Serious events: 0 serious events
Other events: 3 other events
Deaths: 2 deaths
LMP2A CTLs (ALASCER) - Group B DL3
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
LMP2A CTLs (ALASCER) - Group C DL1
Serious events: 1 serious events
Other events: 4 other events
Deaths: 3 deaths
LMP2A CTLs (ALASCER) - Group C DL2
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
LMP2A CTLs (ALASCER) - Group C DL3
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
LMP1/2 CTLs (ALCI) - Group A DL1
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
LMP1/2 CTLs (ALCI) - Group A DL2
Serious events: 1 serious events
Other events: 4 other events
Deaths: 1 deaths
LMP1/2 CTLs (ALCI) - Group A DL3
Serious events: 1 serious events
Other events: 5 other events
Deaths: 1 deaths
LMP1/2 CTLs (ALCI) - Group B DL1
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
LMP1/2 CTLs (ALCI) - Group B DL2
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
LMP1/2 CTLs (ALCI) - Group B DL3
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
LMP1/2 CTLs (ALCI) - Group C DL1
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
LMP1/2 CTLs (ALCI) - Group C DL2
Serious events: 0 serious events
Other events: 3 other events
Deaths: 2 deaths
LMP1/2 CTLs (ALCI) - Group C DL3
Serious events: 1 serious events
Other events: 4 other events
Deaths: 1 deaths
LMP1/2 CTLs (ALCI) - Group A Expansion
Serious events: 3 serious events
Other events: 16 other events
Deaths: 7 deaths
LMP1/2 CTLs (ALCI) - Group B Expansion
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
LMP1/2 CTLs (ALCI) - Group C Expansion
Serious events: 1 serious events
Other events: 3 other events
Deaths: 1 deaths
Serious adverse events
| Measure |
LMP2A CTLs (ALASCER) - Group A DL1
n=3 participants at risk
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group A DL2
n=6 participants at risk
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group A DL3
n=3 participants at risk
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL1
n=3 participants at risk
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL2
n=3 participants at risk
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL3
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL1
n=4 participants at risk
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL2
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL3
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL1
n=3 participants at risk
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL2
n=4 participants at risk
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL3
n=5 participants at risk
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL1
n=3 participants at risk
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL2
n=3 participants at risk
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL3
n=3 participants at risk
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL1
n=3 participants at risk
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL2
n=3 participants at risk
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL3
n=4 participants at risk
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A Expansion
n=16 participants at risk
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B Expansion
n=2 participants at risk
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C Expansion
n=3 participants at risk
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cardiac disorders
Nodal/junctional arrhythmia/dysrhythmia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Cardiac disorders
Supraventricular arrhythmias (SVT/atrial fibrillation/flutter)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Cardiac disorders
Cardiac-ischemia/infarction
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
General disorders
Fatigue (lethargy, malaise, asthenia)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Skin and subcutaneous tissue disorders
Uticaria (hives, welts, wheals)
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Infections and infestations
Wound-Infectious
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Anorexia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Bilirubin
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
SGOT (AST) (serum glutamic oxaloacetic transaminase)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Blood and lymphatic system disorders
Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Infections and infestations
Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia (ANC <1.0 x 10e
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Infections and infestations
Infection without neutropenia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Hyponatremia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Nervous system disorders
Dizziness/lightheadedness
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Nervous system disorders
Neuropathy - Motor
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
20.0%
1/5 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Respiratory, thoracic and mediastinal disorders
Adult respiratory distress syndrome (ARDS)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Vascular disorders
Pulmonary-Other:pulmonaryembolism
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Secondary Malignancy-Other
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SecondaryMalignancy-Other:PERIPHERALPRIMITIVENEUROECTODERMALTUMOR/ EWINGSARCOMA
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SecondaryMalignancy-Other:SpindleCellSarcoma-periaortic
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SecondaryMalignancy-Other:Squamouscellcarcinoma
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
Other adverse events
| Measure |
LMP2A CTLs (ALASCER) - Group A DL1
n=3 participants at risk
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group A DL2
n=6 participants at risk
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group A DL3
n=3 participants at risk
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/ leiomyosarcoma or who are at risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL1
n=3 participants at risk
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL2
n=3 participants at risk
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group B DL3
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL1
n=4 participants at risk
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL2
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP2A CTLs (ALASCER) - Group C DL3
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL1
n=3 participants at risk
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL2
n=4 participants at risk
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A DL3
n=5 participants at risk
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL1
n=3 participants at risk
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL2
n=3 participants at risk
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B DL3
n=3 participants at risk
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL1
n=3 participants at risk
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL2
n=3 participants at risk
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 1 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C DL3
n=4 participants at risk
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 1 x 10\^8 cells/m2, Day14: 2 x 10\^8 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group A Expansion
n=16 participants at risk
Group A: Participants receiving CTLs as therapy for relapsed Lymphoma/ Lymphoepithelioma/ leiomyosarcoma or who are at high risk for relapse.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group B Expansion
n=2 participants at risk
Group B: Participants receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
LMP1/2 CTLs (ALCI) - Group C Expansion
n=3 participants at risk
Group C: Participants receiving CTLs following allogeneic stem cell transplant.
Dose: Participants were administered 2 injections, 14 days apart (Day0: 2 x 10\^7 cells/m2, Day14: 2 x 10\^7 cells/m2).
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Respiratory, thoracic and mediastinal disorders
Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
2/6 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
20.0%
1/5 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Respiratory, thoracic and mediastinal disorders
Allergy/Immunology-Other
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Respiratory, thoracic and mediastinal disorders
Allergy/Immunology-Other:Sorethroat
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Respiratory, thoracic and mediastinal disorders
Allergy/Immunology-Other:excessmucus
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Immune system disorders
Allergy/Immunology-Other:lymphnodeswelling
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Immune system disorders
Allergy/Immunology-Other:moresignificanthistaminereaction
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Ear and labyrinth disorders
Auditory/Hearing-Other
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Blood and lymphatic system disorders
Hemoglobin-Hgb
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
2/6 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
100.0%
3/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
75.0%
3/4 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
100.0%
3/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 8 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
40.0%
2/5 • Number of events 6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 12 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 8 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
43.8%
7/16 • Number of events 16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Leukocytes (total WBC)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
2/6 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
60.0%
3/5 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
100.0%
3/3 • Number of events 8 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 14 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
100.0%
3/3 • Number of events 8 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 23 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
75.0%
3/4 • Number of events 23 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
81.2%
13/16 • Number of events 26 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
100.0%
2/2 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Leukopenia (total WBC)
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
3/6 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Lymphopenia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
83.3%
5/6 • Number of events 15 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 7 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
80.0%
4/5 • Number of events 7 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
100.0%
3/3 • Number of events 6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 10 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
100.0%
3/3 • Number of events 9 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 18 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
62.5%
10/16 • Number of events 28 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
1/2 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Neutrophils/granulocytes (ANC/AGC)
|
66.7%
2/3 • Number of events 6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
4/6 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 8 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 9 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
60.0%
3/5 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 17 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
100.0%
3/3 • Number of events 8 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 24 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
75.0%
3/4 • Number of events 24 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
56.2%
9/16 • Number of events 17 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Platelets
|
66.7%
2/3 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
2/6 • Number of events 6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
75.0%
3/4 • Number of events 12 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
20.0%
1/5 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 8 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
75.0%
3/4 • Number of events 9 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
37.5%
6/16 • Number of events 13 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Blood and lymphatic system disorders
Transfusion: pRBCs
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Blood and lymphatic system disorders
Transfusion; Platelets
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 12 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Blood and lymphatic system disorders
Transfusion; pRBC's
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Vascular disorders
Hypertension
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Vascular disorders
Hypotension
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Cardiac disorders
Sinus Tachycardia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
General disorders
Edema
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Fibrinogen
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Partial thromboplastin time (PTT)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Prothrombin time (PT)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
General disorders
Constitutional Symptoms-Other
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
General disorders
Fatigue (lethargy, malaise, asthenia)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
3/6 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
100.0%
4/4 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
40.0%
2/5 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
4/16 • Number of events 7 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
General disorders
Fever (in the absence of neutropenia, where neutropenia is defined as AGC<1.0 x 10e9/L)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
20.0%
1/5 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
12.5%
2/16 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
General disorders
Fever-absence of Neutropenia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
3/6 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
General disorders
Rigors, chills
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
General disorders
Rigors/Chills
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
General disorders
Sweating (Diaphoresis)
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
General disorders
Sweating (diaphoresis)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Weight loss
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Death not associated with CTCAE term - Disease progression NOS
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Injury, poisoning and procedural complications
Bruising (absence of thrombocytopenia grade 3/4)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Injury, poisoning and procedural complications
Bruising (in absence of grade 3 or 4 thrombocytopenia)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Skin and subcutaneous tissue disorders
Dermatology/Skin-Other
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Skin and subcutaneous tissue disorders
Dermatology/Skin-Other:Face&neckpimples
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Skin and subcutaneous tissue disorders
Dermatology/Skin-Other:SpongioticDermatitis
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Skin and subcutaneous tissue disorders
Dermatology/Skin-Other:pimples
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Skin and subcutaneous tissue disorders
Dry Skin
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
20.0%
1/5 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Skin and subcutaneous tissue disorders
Rash/Desquamation
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
2/6 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Skin and subcutaneous tissue disorders
Rash/desquamation
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
75.0%
3/4 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
12.5%
2/16 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Infections and infestations
Wound-Infectious
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Vascular disorders
Hot Flashes/Flushes
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Anorexia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Gastrointestinal disorders
Diarrhea (without colostomy)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Gastrointestinal disorders
Diarrhea patients without colostomy
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Gastrointestinal disorders
Dyspepsia/Heartburn
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Gastrointestinal disorders
Gastrointestinal-Other
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Gastrointestinal disorders
Gastrointestinal-Other:erythemaofpharynx
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
18.8%
3/16 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Infections and infestations
Stomatitis/pharyngitis (oral/pharyngeal mucositis)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Nervous system disorders
Taste disturbance (dysgeusia)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
2/6 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
20.0%
1/5 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Renal and urinary disorders
Hematuria (in the absence of vaginal bleeding)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
General disorders
Hemorrhage/Bleeding w/gr 3/4 Thrombocytopenia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Skin and subcutaneous tissue disorders
Petechiae/Purpura(hemorrhage/bleeding skin/mucosa)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Alkaline phosphatase
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Bilirubin
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
1/2 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Hepatic-Other:Hypoproteinemia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Hypoalbuminemia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
SGOT (AST) (serum glutamic oxaloacetic transaminase)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
2/6 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
40.0%
2/5 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
100.0%
3/3 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
100.0%
3/3 • Number of events 11 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
31.2%
5/16 • Number of events 8 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
1/2 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
SGPT (ALT) (serum glutamic pyruvic transaminase)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
20.0%
1/5 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Alkaline Phosphatase
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Hepatobiliary disorders
Hepatic-Other
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
SGOT(AST) (serum glutamic oxal. Transaminase)
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
75.0%
3/4 • Number of events 6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
SGPT(ALT) (seurm glutamic pyruric trans.)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Blood and lymphatic system disorders
Febrile Neutropenia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Infections and infestations
Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia (ANC <1.0 x 10e
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Infections and infestations
Infection without Neutropenia
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Infections and infestations
Infection without neutropenia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
20.0%
1/5 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
68.8%
11/16 • Number of events 14 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
100.0%
3/3 • Number of events 6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Blood and lymphatic system disorders
Lymphatics-Other
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Blood and lymphatic system disorders
Lymphatics-Other:cervicaladenopathy
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Acidosis (metabolic or respiratory)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Alkalosis (metabolic or respiratory)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Amylase
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Bicarbonate
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
100.0%
4/4 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
40.0%
2/5 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 10 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
12.5%
2/16 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Hypercalcemia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Hypercholesterolemia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
33.3%
1/3 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
2/6 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 10 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 11 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
20.0%
1/5 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
100.0%
3/3 • Number of events 7 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
12.5%
2/16 • Number of events 12 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Hyperkalemia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
40.0%
2/5 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Hypermagnesemia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Hypernatremia
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
12.5%
2/16 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Hypertriglyceridemia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Hyperuricemia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Hypocalcemia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 7 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
20.0%
1/5 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 11 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
18.8%
3/16 • Number of events 6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Hypokalemia
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
4/6 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
75.0%
3/4 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
60.0%
3/5 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 12 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 11 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
4/16 • Number of events 8 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
1/2 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Hypomagnesmia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
12.5%
2/16 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Hyponatremia
|
33.3%
1/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
20.0%
1/5 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
12.5%
2/16 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 8 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Hypophosphatemia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Lipase
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Metabolism and nutrition disorders
Metabolic/Laboratory-Other
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
100.0%
4/4 • Number of events 7 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Metabolic/Laboratory-Other:Hyperchloremia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Metabolic/Laboratory-Other:Hypochloremia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Musculoskeletal and connective tissue disorders
Musculoskelatal-Other
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Nervous system disorders
Depressed level of consciousness
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Nervous system disorders
Dizziness/Lightheadedness
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Nervous system disorders
Dizziness/lightheadedness
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
12.5%
2/16 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Psychiatric disorders
Mood alteration-anxiety, agitation
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Injury, poisoning and procedural complications
Neurology-Other:Fall
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Nervous system disorders
Neuropathy - motor
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
20.0%
1/5 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Nervous system disorders
Neuropathy-Sensory
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Eye disorders
Conjunctivitis
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
20.0%
1/5 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Eye disorders
Dry Eye
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Eye disorders
Ocular-Visual Other
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
2/6 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Eye disorders
Ocular/Visual-Other:Periorbitalerythemaandswelling
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Eye disorders
Ocular/Visual-Other:Visionhaziness
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Eye disorders
Tearing (watery eyes)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Gastrointestinal disorders
Abdominal Pain or Cramping
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Gastrointestinal disorders
Abdominal pain or cramping
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
12.5%
2/16 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia (joint pain)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Musculoskeletal and connective tissue disorders
Bone Pain
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
General disorders
Chest Pain (non-cardiac, non-pleuritic)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
General disorders
Chest pain (non-cardiac and non-pleuritic)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Nervous system disorders
Headache
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
4/6 • Number of events 6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Musculoskeletal and connective tissue disorders
Myalgia (muscle pain)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Nervous system disorders
Neuropathic Pain
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
General disorders
Pain-Other
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
75.0%
3/4 • Number of events 9 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Musculoskeletal and connective tissue disorders
Pain-Other:Ankle,backandknee
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Musculoskeletal and connective tissue disorders
Pain-Other:Legpain
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Gastrointestinal disorders
Pain-Other:Oralpain
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Respiratory, thoracic and mediastinal disorders
Pain-Other:SORETHROAT
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Musculoskeletal and connective tissue disorders
Pain-Other:bodyaches
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Musculoskeletal and connective tissue disorders
Pain-Other:generalizedaches&pains
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Musculoskeletal and connective tissue disorders
Pain-Other:lefthandpain
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Musculoskeletal and connective tissue disorders
Pain-Other:leftshoulder
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Musculoskeletal and connective tissue disorders
Pain-Other:upperrightarm
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumor pain (onset or exacerbation of tumor pain due to treatment)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea (shortness of breath)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary-Other
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary-Other:Reactiveairwaydisease
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary-Other:SORETHROAT
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary-Other:Tachypnea
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Respiratory, thoracic and mediastinal disorders
Voice changes/stridor/larynx (e.g., hoarseness, loss of voice, laryngitis)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
20.0%
1/5 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary-Other:RespiratoryFailure
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary-Other:sorethroat
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Creatinine
|
66.7%
2/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
20.0%
1/5 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
66.7%
2/3 • Number of events 3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
12.5%
2/16 • Number of events 5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Renal and urinary disorders
Dysuria (painful urination)
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Renal/Genitourinary-Other
|
33.3%
1/3 • Number of events 2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
50.0%
2/4 • Number of events 4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Investigations
Renal/Genitourinary-Other:BUN
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
33.3%
1/3 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Renal and urinary disorders
Urinary Frequency/Urgency
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
25.0%
1/4 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SecondaryMalignancy-Other:Highgradesarcoma
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SecondaryMalignancy-Other:MyelodysplasticSyndrome
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
16.7%
1/6 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/16 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SecondaryMalignancy-Other:squamouscellcarcinoma
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/6 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
—
0/0 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/5 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/4 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
6.2%
1/16 • Number of events 1 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/2 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
0.00%
0/3 • Data on adverse experiences/toxicities regardless of seriousness were collected for documentation purposes only for 6 weeks after the last dosing of the study drug/biologic.
Zeros in the number of participants at risk for Other/Serious Adverse Events and the number of participants at risk for All-Cause Mortality are due to no participants treated at those arms/groups. One participant in the LMP1/2 CTLs (ALCI) - Group A Expansion was enrolled to this arm/group twice. All adverse event data is included for this participant regardless of enrollment.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place